GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » PensionAndRetirementBenefit

CytoMed Therapeutics (CytoMed Therapeutics) PensionAndRetirementBenefit : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics PensionAndRetirementBenefit?

CytoMed Therapeutics's PensionAndRetirementBenefit for the quarter that ended in Dec. 2023 was $0.00 Mil.


CytoMed Therapeutics PensionAndRetirementBenefit Historical Data

The historical data trend for CytoMed Therapeutics's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics PensionAndRetirementBenefit Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - - -

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PensionAndRetirementBenefit Get a 7-Day Free Trial - - - - -

CytoMed Therapeutics PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Traded in Other Exchanges
Address
1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Executives
Chee Kong Choo director, 10 percent owner COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng director, officer: CSO and CMO 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang 10 percent owner 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan director, officer: Chief Operating Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd 10 percent owner 18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee director, officer: Chief Clinical Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh director 1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544